FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010205433> ?p ?o ?g. }

• W2010205433 endingPage "175" @default.
• W2010205433 startingPage "160" @default.
• W2010205433 abstract "Immunotherapy using autologous T cells has emerged to be a powerful treatment option for patients with metastatic melanoma. These include the adoptive transfer of autologous tumor-infiltrating lymphocytes (TILs), T cells transduced with high-affinity T cell receptors against major tumor antigens, and T cells transduced with chimeric antigen receptors composed of hybrid immunoglobulin light chains with endodomains of T-cell signaling molecules. Among these and other options for T-cell therapy, TILs together with high-dose interleukin 2 have had the longest clinical history with multiple clinical trials in centers across the world consistently demonstrating durable clinical response rates near 50% or more. A distinct advantage of TIL therapy making it still the T-cell therapy of choice is the broad nature of the T-cell recognition against both defined and undefined tumors antigens against all possible major histocompatibility complex, rather than the single specificity and limited major histocompatibility complex coverage of the newer T cell receptors and chimeric antigen receptor transduction technologies. In the past decade, significant inroads have been made in defining the phenotypes of T cells in TIL-mediating tumor regression. CD8+ T cells are emerging to be critical, although the exact subset of CD8+ T cells exhibiting the highest clinical activity in terms of memory and effector markers is still controversial. We present a model in which both effector-memory and more differentiated effector T cells ultimately may need to cooperate to mediate long-term tumor control in responding patients. Although TIL therapy has shown great potential to treat metastatic melanoma, a number of issues have emerged that need to be addressed to bring it more into the mainstream of melanoma care. First, we have a reached the point where a pivotal phase II or phase III trial is needed in an attempt to gain regulatory approval of TILs as standard of care. Second, improvements in how we expand TILs for therapy are needed that minimize the time the T cells are in culture and improve the memory and effector characteristics of the T cells for longer persistence and enhanced anti-tumor activity in vivo. Third, there is a critical need to identify surrogate and predictive biomarkers to better select suitable patients for TIL therapy to improve response rate and duration. Overall, the outlook for TIL therapy for melanoma is very bright. We predict that TILs will indeed emerge to become an approved treatment in the upcoming years through pivotal clinical trials. Moreover, new approaches combining TILs with targeted signaling pathway drugs, such as mutant B-RAF inhibitors, and synergistic immunomodulatory interventions enhancing T-cell costimulation and preventing negative regulation should further increase therapeutic efficacy and durable complete response rates." @default.
• W2010205433 created "2016-06-24" @default.
• W2010205433 creator A5021932370 @default.
• W2010205433 creator A5033798832 @default.
• W2010205433 creator A5050132330 @default.
• W2010205433 creator A5051328429 @default.
• W2010205433 creator A5054532514 @default.
• W2010205433 creator A5060265796 @default.
• W2010205433 creator A5079205751 @default.
• W2010205433 creator A5083694976 @default.
• W2010205433 date "2012-03-01" @default.
• W2010205433 modified "2023-10-13" @default.
• W2010205433 title "Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma" @default.
• W2010205433 cites W1487731794 @default.
• W2010205433 cites W1592864174 @default.
• W2010205433 cites W1594345612 @default.
• W2010205433 cites W1624657716 @default.
• W2010205433 cites W1672186364 @default.
• W2010205433 cites W1736513025 @default.
• W2010205433 cites W1761214387 @default.
• W2010205433 cites W1767113662 @default.
• W2010205433 cites W1823669223 @default.
• W2010205433 cites W1957293994 @default.
• W2010205433 cites W1965598536 @default.
• W2010205433 cites W1971037354 @default.
• W2010205433 cites W1972197089 @default.
• W2010205433 cites W1979936799 @default.
• W2010205433 cites W1982374707 @default.
• W2010205433 cites W1983412131 @default.
• W2010205433 cites W1983923482 @default.
• W2010205433 cites W1986426976 @default.
• W2010205433 cites W1990392443 @default.
• W2010205433 cites W1991287153 @default.
• W2010205433 cites W1991385476 @default.
• W2010205433 cites W1992108489 @default.
• W2010205433 cites W1994340919 @default.
• W2010205433 cites W1997283102 @default.
• W2010205433 cites W2000297273 @default.
• W2010205433 cites W2003465496 @default.
• W2010205433 cites W2010121426 @default.
• W2010205433 cites W2015054461 @default.
• W2010205433 cites W2016612145 @default.
• W2010205433 cites W2016671320 @default.
• W2010205433 cites W2016789384 @default.
• W2010205433 cites W2017209592 @default.
• W2010205433 cites W2018540827 @default.
• W2010205433 cites W2019607817 @default.
• W2010205433 cites W2020099065 @default.
• W2010205433 cites W2028714411 @default.
• W2010205433 cites W2030454288 @default.
• W2010205433 cites W2030578708 @default.
• W2010205433 cites W2031311358 @default.
• W2010205433 cites W2034244225 @default.
• W2010205433 cites W2034359690 @default.
• W2010205433 cites W2034745242 @default.
• W2010205433 cites W2034867641 @default.
• W2010205433 cites W2036481615 @default.
• W2010205433 cites W2036657064 @default.
• W2010205433 cites W2036905020 @default.
• W2010205433 cites W2046183929 @default.
• W2010205433 cites W2047681784 @default.
• W2010205433 cites W2047902191 @default.
• W2010205433 cites W2049891831 @default.
• W2010205433 cites W2050297562 @default.
• W2010205433 cites W2050302632 @default.
• W2010205433 cites W2050545961 @default.
• W2010205433 cites W2052587346 @default.
• W2010205433 cites W2053848197 @default.
• W2010205433 cites W2055175265 @default.
• W2010205433 cites W2058899594 @default.
• W2010205433 cites W2061952839 @default.
• W2010205433 cites W2064706357 @default.
• W2010205433 cites W2064718707 @default.
• W2010205433 cites W2067271486 @default.
• W2010205433 cites W2067963142 @default.
• W2010205433 cites W2068402566 @default.
• W2010205433 cites W2069401298 @default.
• W2010205433 cites W2069578209 @default.
• W2010205433 cites W2071548401 @default.
• W2010205433 cites W2072502005 @default.
• W2010205433 cites W2074604431 @default.
• W2010205433 cites W2075320686 @default.
• W2010205433 cites W2075820095 @default.
• W2010205433 cites W2076335749 @default.
• W2010205433 cites W2076723714 @default.
• W2010205433 cites W2076991609 @default.
• W2010205433 cites W2080568999 @default.
• W2010205433 cites W2081902304 @default.
• W2010205433 cites W2082930742 @default.
• W2010205433 cites W2083817201 @default.
• W2010205433 cites W2087360163 @default.
• W2010205433 cites W2089401318 @default.
• W2010205433 cites W2091110863 @default.
• W2010205433 cites W2092003421 @default.
• W2010205433 cites W2092972513 @default.
• W2010205433 cites W2094652659 @default.
• W2010205433 cites W2096522498 @default.
• W2010205433 cites W2097074641 @default.

• next